KATE CLARK: Open Payments
NPI 1780052183 · NAMPA, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,853 in 43 payments from 8 companies in 2025. Trend: 2023 $1,176 · 2024 $981 · 2025 $1,853
Food & beverage: $1,735Education: $119
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 6 | $590 |
| Teva Pharmaceuticals USA, Inc. | 12 | $349 |
| Neurocrine BioSciences, Inc. | 11 | $223 |
| Otsuka America Pharmaceutical, Inc. | 4 | $215 |
| Janssen Pharmaceuticals, Inc | 7 | $187 |
| Axsome Therapeutics, Inc. | 1 | $123 |
| Supernus Pharmaceuticals, Inc. | 1 | $101 |
| ABBVIE INC. | 1 | $64 |
Products named: COBENFY, AUSTEDO XR, INGREZZA, ABILIFY MAINTENA, INVEGA SUSTENNA, Auvelity, Qelbree, VRAYLAR.
Industry payments across ID — which companies pay providers there.
